Skip to main content
. Author manuscript; available in PMC: 2013 Jun 24.
Published in final edited form as: Mol Cell Endocrinol. 2012 Dec 23;371(0):189–194. doi: 10.1016/j.mce.2012.12.011

Figure 2.

Figure 2

Anti-tumor effects of peptide analogs targeting ss2, LHRHR and GHRHR in MPC. AN-162 and AN-238 significantly influenced MPC cell viability over 24–72h (A) and highly significant increased caspase 3/7 activity (B) over 24–72h (10−6 mol/l). Similarly, GHRH antagonist MIA-602, LHRH antagonist Cetrorelix and LHRH analog AN-152 reduced MPC cell viability (C). AN-152 also significantly increased programmed MPC cell death (D) (n= 3–6, *P < 0.05, **P < 0.01, ***P < 0.001 as compared to control for all assays).